Metformin has been shown to decrease AKT activity in breast cancer cells and in glioma stem cells through insulin-receptor signaling, which is another potential mechanism for metformin’s anti-neoplastic activity [32, 43, 44]. The gene discussed is AKT1; the disease is breast carcinoma.